iNtRON Biotechnology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for iNtRON Biotechnology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	82.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

Nov 15

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Mar 24

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

Feb 28

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 31

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

Dec 10

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

Nov 26

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iNtRON Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A048530 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	8,615	-4,816	-6,117	699	N/A
6/30/2024	9,078	-6,091	-6,080	1,608	N/A
3/31/2024	9,422	-8,518	-2,021	5,920	N/A
12/31/2023	9,585	-9,695	-4,931	3,118	N/A
9/30/2023	8,302	-9,560	120	3,010	N/A
6/30/2023	9,460	-8,652	2,132	4,697	N/A
3/31/2023	10,070	5,372	1,927	4,397	N/A
12/31/2022	14,007	5,712	3,360	5,977	N/A
9/30/2022	19,681	8,015	10,260	12,432	N/A
6/30/2022	24,569	11,708	10,511	12,642	N/A
3/31/2022	29,587	7,149	11,178	13,510	N/A
12/31/2021	29,308	9,728	13,129	16,473	N/A
9/30/2021	33,002	14,948	8,341	12,461	N/A
6/30/2021	32,293	14,948	6,028	9,634	N/A
3/31/2021	47,899	16,886	9,669	14,173	N/A
12/31/2020	45,433	14,948	2,309	7,131	N/A
9/30/2020	35,831	7,677	1,208	4,239	N/A
6/30/2020	30,683	2,915	1,532	4,780	N/A
3/31/2020	9,851	-3,396	-3,354	-1,302	N/A
12/31/2019	8,347	-3,187	-1,485	-812	N/A
9/30/2019	19,952	10,876	8,443	9,308	N/A
6/30/2019	19,997	9,268	7,038	7,771	N/A
3/31/2019	19,988	9,739	4,495	5,353	N/A
12/31/2018	20,584	8,711	3,467	4,200	N/A
9/30/2018	9,991	-7,018	-8,197	-7,559	N/A
6/30/2018	10,345	-2,844	N/A	-7,991	N/A
3/31/2018	10,915	-10,056	N/A	-6,361	N/A
12/31/2017	10,963	-8,734	N/A	-5,468	N/A
9/30/2017	11,000	-5,271	N/A	-7,442	N/A
6/30/2017	10,959	-5,448	N/A	-5,862	N/A
3/31/2017	10,296	-2,146	N/A	-5,502	N/A
12/31/2016	10,222	-2,252	N/A	-4,644	N/A
12/31/2015	11,835	1,558	N/A	1,699	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A048530's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A048530's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A048530's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A048530's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A048530's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A048530's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 17:40
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

iNtRON Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sangsoo Kim	Goldman Sachs

iNtRON Biotechnology Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to ₩16,400

Price target decreased to ₩16,400

Recent updates

Upcoming dividend of ₩100.00 per share

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Full year 2023 earnings released: ₩292 loss per share (vs ₩168 profit in FY 2022)

Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment improves as stock rises 30%

iNtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome

Full year 2022 earnings released: EPS: ₩168 (vs ₩288 in FY 2021)

Investor sentiment deteriorates as stock falls 15%

iNtRON Biotechnology, Inc. Confirms the Efficacy of BAL200, A Novel Endolysin Biologic for Inhalational Anthrax

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Price target decreased to ₩16,400

iNtRON Developed Advanced Bacteriophage Engineering Platform Technology Based on Modified Random Mutagenesis

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Develops New CRISPR/Cas Technology Specific for Bacteriophage as PHAGERUS® Platform

iNtRON Biotechnology, Inc. Confirms Efficacy of Cdl200 Against CDI Clinical Isolates

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology Completes GLP-TOX Studies of BAL200

Price target decreased to ₩16,400

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology, Inc. announced that it has received KRW 40 billion in funding

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

iNtRON Biotechnology, Inc., Annual General Meeting, Mar 25, 2021

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

New 90-day high: ₩23,000

Investor sentiment improved over the past week

Market bids up stock over the past week

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

New 90-day high: ₩17,050

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

New 90-day low: ₩13,800

New 90-day high - ₩18,100

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources